<DOC>
	<DOCNO>NCT00504335</DOCNO>
	<brief_summary>This trial design evaluate safety pharmacokinetics BIO 300 capsule administer orally healthy male female volunteer . BIO 300 expect safe use start 500 mg .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study BIO 300 Capsules</brief_title>
	<detailed_description>This clinical trial ass safety PK BIO 300 capsule dos expect deliver radioprotective therapeutic effect human . Humanetics plan conduct Phase I , single dose , dose-escalation ( 500 , 1000 , 1500 , 2000 milligram ) study safety , tolerability pharmacokinetics BIO 300 recruit approximately 24 healthy men woman age 18 64 enrol cohort 6 subject per group . The first cohort receive one 500 mg BIO 300 capsule pharmacokinetic blood sampling conduct first 4 day outpatient set clinic skilled type Phase I trial . Blood sample analyze BIO 300 level , hematology , chemistry , lipid profile , phosphorus , clot factor fibrinogen well pancreatic lipase amylase . Urinalysis assess kidney function well creatinine clearance BIO 300 clearance . All subject monitor adverse event safety BIO 300 capsule evaluate set . After review safety information provide clinically significant negative finding reveal , second cohort treat 1000mg BIO 300 ( two 500mg capsule ) use PK sample program . Again safety concern review provide clinically significant negative finding reveal , third fourth cohort treat 1500 2000 mg , respectively , BIO 300 use PK sample program .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Radiation Syndrome</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>Healthy male female subject , age 1864 , sign consent form Subjects body mass index ( BMI ) 1830 kg/m2 Subjects willing abstain sex use barrier method birth control ( Women 1 week , Men 4 month leave trial ) Subjects negative pregnancy test drug screen Subjects laboratory value within normal limit ( CBC/differential , CMP , enzymes , ECG , vital sign , urinalysis ) Subjects ability comprehend complete questionnaire form Subjects likely comply study procedure test article consumption Subjects whose schedule permit 1012 hour stay clinic follow daily evaluation one week ( 7 day ) Subjects available 14day follow phone call ( woman ) 4month follow phone call ( men ) . Subjects likely abstain take unauthorized medication supplement participate clinical trial experimental treatment trial Subjects likely follow low isoflavone diet program Â· Subjects allergic reaction sensitivity soy , isoflavones , component test article product Subjects consume &gt; 5 alcoholic beverage per week Subjects pregnant , lactating , risk become pregnant Subjects blood ( urine ) level outside normal range hepatic , renal , hematologic , lipid coagulation parameter measure . Subjects Hormone Replacement Therapy Birth Control Pills within past three month . Subjects clinical trial experimental treatment past 3 month Subjects history diabetes ( Type 1 Type 2 diabetes mellitus ) endocrine disorder , uncontrolled hypertension , prior cerebrovascular accident seizure disorder , cardiovascular , hepatic renal disease , active cancer , hematologic disorder , thromboembolic disease , HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Acute Radiation Syndrome</keyword>
	<keyword>Hematopoietic Syndrome</keyword>
	<keyword>Radiation Injury</keyword>
	<keyword>BIO 300</keyword>
</DOC>